Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

cessful NDA filing and furthering our discussions with potential collaboration partners."

Based upon the discussions with FDA, Palatin intends to finalize the protocols for the pivotal Phase 3 clinical studies and start screening patients later this year.

Quarter Ended March 31, 2013 Financial Results
For the three months ended March 31, 2013, Palatin reported a net loss of $4.0 million, or $(0.04) per basic and diluted share, compared to a net loss of $6.0 million, or $(0.17) per basic and diluted share, for the same period in 2012. 

The decrease in net loss for the quarter ended March 31, 2013, compared to the same period last fiscal year, is attributable to a decrease in operating expenses primarily related to Palatin's Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of FSD. 

Revenue
Palatin did not recognize any revenues for the quarter ended March 31, 2013, compared to $23,996 for the quarter ended March 31, 2012.  Revenue consists of contract revenue under our collaboration agreement with AstraZeneca.

Costs and Expenses
Total operating expenses for the quarter ended March 31, 2013 were $4.0 million compared to $6.1 million for the comparable quarter of 2012.  The decrease in operating expenses for the quarter was primarily due to Palatin's Phase 2B clinical trial with bremelanotide for FSD and secondarily as a result of closing our research laboratory operations in connection with the lease expiration of the laboratory facilities in July 2012.

Cash Position
As of March 31, 2013, Palatin had cash and cash equivalents of $23.5 million, $6.0 million in short term investments and current liabilities of $2.7 million.  Cash and cash equivalents as of June 30, 2012 were $3.8 million with current liabilities of $3.5 million. 

Palatin believes that its existing capital resources will be adequate to fund its currently planned opera
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
3. Palatin Technologies To Present At The 25th Annual ROTH Conference
4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 This report is a ... industry. For an overview analysis, the report introduces ... chain structure, industry overview, policy analysis, and news ... has witnessed rapid development with key manufacturers ... This report mentions quartz tubing upstream raw materials ...
(Date:12/17/2014)... SPRING, Md. , Dec. 17, 2014  United ... two senior executive promotions as well as changes to ... Senior Executive Promotions United Therapeutics ... to President and Co-Chief Executive Officer and David ... Operating Officer.  In connection with these promotions, Dr. Rothblatt,s ...
(Date:12/15/2014)... YORK & PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI ), a leading developer ... today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was ... Israel,s Office of the Chief Scientist ... been in receipt of grant support from the Office ...
(Date:12/13/2014)... 13, 2014 CanDiag, Inc., a University ... has changed its name to OncoTab, Inc. , ... where we are today,” said CEO and Chief Science ... applications beyond breast cancer diagnostics to include imaging and ... that evolution.” , Founded in 2011 by Dr. Mukherjee, ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2
... 20, 2011 Scientists Drs. Samuel and Elenore Bogoch of ... increase in Replikin Counts of the EHEC lethal strains of ... strains of E. Coli have been studied in laboratories in ... available in the public databases. Replikins are subsequences of the ...
...   Hospitals, health systems to ... Sigma and other,performance management solutions ... information products,and services, has struck an exclusive partnership with ... online learning solutions for process,improvement. Elsevier will ...
... has the potential to make consumer electronic devices faster ... scale of electronics, also make graphene difficult to fabricate ... In September 2010, a UCLA research team reported ... were able to fabricate graphene transistors with unparalleled speed. ...
Cached Biology Technology:Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 3Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 2Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 3Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 4UCLA team reports scalable fabrication of self-aligned graphene transistors, circuits 2
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a ... that its U.are.U ® fingerprint readers have been ... in Central Mexico . The bakery ... to eliminate payroll issues caused by employees clocking in ... the U.are.U fingerprint readers, Montparnasse relied on paper timecards ...
(Date:11/10/2014)... U.S. store shelves in early 2010, and people have ... packets can be tossed into a washing machine without ... The convenience, though, has come with risks for young ... Children,s Hospital found that from 2012 through 2013, U.S. ... than 6 years of age swallowing, inhaling, or otherwise ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Study finds laundry detergent pods, serious poisoning risk for children 2
... Jan. 7, 2013 Halting climate change will require "a ... eradicate harmful carbon dioxide emissions, not just stabilize them, according ... In a Jan. 9 paper in Environmental Research Letters ... take a fresh look at the popular "wedge" approach to ...
... from Italy and their offspring form one of the largest ... their state of health and risk of mortality. In a ... University of Zurich,s Institute of Social and Preventative Medicine calculated ... Immigrants from Italy live longer than ...
... New research led by the Karolinska Institutet, Sweden and the ... human gene and the composition of human gastrointestinal bacteria. In ... Gut , the team outline new evidence suggesting that the ... of the billions of microbes in the human gastrointestinal tract ...
Cached Biology News:Major cuts to surging CO2 emissions are needed now, not down the road, study finds 2Italian immigrants live longer 2International study suggests human genes influence gut microbial composition 2
... The Jouan MSC series of Class ... working conditions and certification to the ... regulation ensures that the cabinets cannot ... conditions. Natural lighting, low noise and ...
... a dedicated fluorometer with sensitivity ... of assays in industrial and ... applications. Cell biology, immunology and ... application areas. Robot-friendly hardware and ...
... The Holten MaxiSafe 2010 Class ... most ergonomical working condition of comfort ... safety, efficiency and performance.,Refined operator, environment ... of both exhausted and recirculated air.,Bottom ...
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
Biology Products: